Today I want to look at 3 companies that investors should have on their radar screen in the nutritional and homeopathic market.
First is the mid-cap Vitamin Shoppe (NYSE:VSI). The company has seen its stock price go from just under $18 a share in October, 2009 to trading at above $43 currently. During that time the country has seen its revenue grow over 50% and its earnings grow over 500% from $12.7 million to over $66 million.
But the stock has stalled, trading at roughly the same amount it was trading at the same time last year. Which is good news to investors seeking value.
Its latest quarter showed over a 10% increase in revenue. Comparable sales were up 3.6%. The company opened up 9 new stores during the quarter and has increased its total number by 46 over the last year.
There is a lot to be excited about this stock.
GNC (NYSE:GNC) has moved downward since the start of the year, dropping roughly 40% of its value. A big part of that reason was a New York Times article that questioned the effectiveness of vitamin supplements.
But the fundamentals of the company appear very strong. In its latest earnings report the company posted revenue of almost $256 million. This is down slightly from the $256.1 million from the 1st quarter of 2013 but nothing justifying a 40% drop in value.
The company produced earnings per share of $0.75, up from $0.73 from the same quarter last year. In addition GNC declared a $0.16 dividend.
GNC is very profitable, and one aspect of this is the number of proprietary brands the company sells. These brands have higher margins and shield the company from competitors like the Vitamin Shoppe and Amazon. Roughly 80% of the company's sales comes from its proprietary labels.
I also have Itonis, Inc. (OTCPK:ITNS) on my radar. Early in June the company announced that it had completed its National Drug Code application with the FDA and received its NDC number for its anti-nausea drug Emesyl(r).
The company plans to market the drug store retailers and department stores in the coming months.
Emesyl was developed by Dr. Charles Hensley who also developed Zicam, a homeopathic cold remedy that has been around since the mid-1990s. If the drug could have a fraction of the success of Zicam then investors in Itonis would stand to make tremendous gains.
With any company of this size there are considerable risks but the upside is huge. Matrixx Initiatives was the company that owned and marketed Zicam. In 2011 Matrixx was purchased by H.I.G. Capital for $8.75 a share, or a little over $75 million. A fraction of such a payoff might be worth the risk for this company.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it. The author has no business relationship with any company whose stock is mentioned in this article.